on Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Protagonist Therapeutics Recognized for Innovation in Biotech
Protagonist Therapeutics, a clinical-stage biopharmaceutical company, has been named one of the World's Most Innovative Companies for 2025 by Fast Company. Recognized for its advancements in peptide-based therapeutics, Protagonist stands out as a top biotechnology innovator.
The company's proprietary development platform has delivered significant candidates like Rusfertide, a potential treatment for polycythemia vera, and Icotrokinra, an oral IL-23 antagonist effective in psoriasis. Both drugs are advancing towards regulatory filings this year. Protagonist aims to provide oral solutions for conditions typically treated with injectables, addressing unmet needs in immunology and metabolic diseases.
Their achievements reflect a strategic focus on innovation and a solid financial foundation extending through 2028. Protagonist's inclusion in Fast Company's list underscores their commitment to pioneering transformative healthcare solutions.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Protagonist Therapeutics, Inc. news